A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT04847557
- Phase
- PHASE3
- Status
- Completed
Conditions
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Obesity
Eligibility Criteria
- Sex
- ALL
- Age
- 40 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Tirzepatide — DRUGAdministered SC
- Placebo — OTHERAdministered SC
Study Details
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
Key Dates
- Start date
- Apr 20, 2021
- Status verified
- Aug 2025
- Primary completion
- Jul 2, 2024
- Completion
- Jul 2, 2024
Study Design
- Enrollment
- 731 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: TirzepatideParticipants received a starting dose of 2.5 milligrams (mg) tirzepatide administered subcutaneously (SC) once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or maximum tolerated dose (MTD) tolerated by the participant (5 mg QW or 10 mg QW).
- Placebo Comparator: PlaceboParticipants received placebo administered SC QW.
Primary Outcome Measure
Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) [ Time Frame: Baseline, Week 52 ]
Locations (54)
Related coverage on Hipa.ai
- Tirzepatide SUMMIT Trial for HFpEF and Obesity Improves KCCQ Scores, Reduces…Tirzepatide · Aug 20, 2025 · ClinicalTrials.gov
Find similar trials in Huntsville, AL
By condition
By specialty
Related Studies
- Diabetes and Heart Disease Risk in BlacksRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Physical and Behavioral Traits of Overweight and Obese AdultsRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
- Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular SystemRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
- New Heart Imaging Techniques to Evaluate Possible Heart DiseaseRecruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland